



## 3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Celeste Porsbjerg<sup>1,2</sup>, Anke H. Maitland-van der Zee<sup>3,4</sup>, Guy Brusselle <sup>5</sup>, Giorgio Walter Canonica <sup>6,7</sup>, Alvar Agusti<sup>8,9</sup>, Rosa Faner<sup>8</sup>, Claus F. Vogelmeier<sup>10,11</sup>, Martijn Nawijn <sup>12</sup>, Maarten van den Berge<sup>13</sup>, Franca Rusconi <sup>14</sup>, Charles Pilette<sup>15</sup>, Valeria Ramiconi<sup>16</sup>, Courtney Coleman<sup>17</sup>, Rekha Chaudhuri<sup>18</sup>, Kian Fan Chung<sup>19</sup>, Jadwiga Wedzicha<sup>19</sup>, Sejla Saglani<sup>19,20</sup>, Marc P. Van der Schee<sup>21</sup>, Liam Heaney<sup>22</sup>, Arnaud Bourdin <sup>23,24</sup>, Graham Roberts<sup>25,26,27</sup>, Ratko Djukanovic<sup>28</sup>, Piotr Kuna<sup>29</sup>, Maceij Kupczyk<sup>29</sup>, Judith Axmann<sup>30</sup>, Heribert Staudinger<sup>31</sup>, Graham W. Clarke<sup>32</sup>, Sven Erik Dahlen<sup>33,34</sup> and Chris Brightling<sup>35</sup>

<sup>1</sup>Dept of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark. <sup>2</sup>Copenhagen Center for Translational Research, Bispebjerg Hospital, Copenhagen, Denmark. <sup>3</sup>Dept of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, Amsterdam, The Netherlands. <sup>5</sup>Dept of Pediatric Pulmonology, Amsterdam UMC, University of Amsterdam, The Netherlands. <sup>5</sup>Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. <sup>6</sup>Personalized Medicine, Asthma and Allergy Humanitas Clinical and Research Center IRCCS, Rozzano, Italy, <sup>7</sup>Dept of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. <sup>8</sup>Hospital Clinic, University of Barcelona, Barcelona, Spain. <sup>9</sup>DIBAPS, CIBERES, Barcelona, Spain. <sup>10</sup>Dept of Medicine, Pulmonary and Critical Care Medicine, University of Marburg (UMR), Marburg, Germany. <sup>11</sup>Member of the German Center for Lung Research (DzL), Marburg, Germany. <sup>12</sup>Dept of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, The Netherlands. <sup>13</sup>Dept of Pulmonary Diseases, University Hospital, Florence, Italy. <sup>15</sup>Dept of pneumology, Cliniques universitaires Saint-Luc and Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium. <sup>16</sup>European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels, Belgium. <sup>17</sup>European Lung Pointiat, College London, London, UK. <sup>20</sup>Dept of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK. <sup>21</sup>Owlstone Medical Ltd, Cambridge, UK. <sup>22</sup>Wellcome-Wolfson Centre for Experimental Medicine, School of Medicine, Ontopellier, Montpellier, France. <sup>24</sup>PhyMedExp, Univ Montpellier, CNRS, INSERM, Montpellier, France. <sup>25</sup>Faculty of Medicine, University of Southampton, UK. <sup>26</sup>Diller David Hide Asthma and Allergy Research Centre, University Hospital, Southampton, NHS <sup>26</sup>Clinical and Experimental Science, Faculty of Medicine and NIHR Southampton Biomedical Research centre, South

Corresponding author: Celeste Porsbjerg (celeste.porsbjerg@regionh.dk)

Check for updates	Shareable abstract (@ERSpublications) 3TR, the largest IMI consortium ever in immune diseases, brings clinical researchers and scientists from several disease areas together, in an endeavour to increase the clinical impact of targeted immune-mediated therapies, including asthma and COPD https://bit.ly/3kPq0xl
	<b>Cite this article as:</b> Porsbjerg C, Maitland-van der Zee AH, Brusselle G, <i>et al.</i> 3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. <i>Eur Respir J</i> 2021; 58: 2102168 [DOI: 10.1183/13993003.02168-2021].
	This single-page version can be shared freely online.
Copyright ©The authors 2021. For reproduction rights and	The 3TR (Taxonomy, Treatments, Targets and Remission) consortium is the largest IMI (Innovative Medicine Initiative) project ever started in the field of immune diseases (https://3tr-imi.eu/). 3TR is unique in bringing several medical specialties, encompassing respiratory medicine, rheumatology, neurology and

permissions contact permissions@ersnet.org

Received: 4 Aug 2021 Accepted: 20 Aug 2021 gastroenterology, together, to study disease mechanisms across seven disease entities: asthma, COPD, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, ulcerative colitis and Crohn's disease.